Clinical Trial Update: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of CD25/Treg-depleted donor lymphocyte infusion with ipilimumab for relapse of myeloid diseases after matched hematopoiet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelofibrosis
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasms

Drugs mentioned

• CD25/Treg-depleted donor lymphocyte infusion
• ipilimumab (ipilimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-05